Compare NTNX & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTNX | GH |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 13.3B |
| IPO Year | 2015 | 2018 |
| Metric | NTNX | GH |
|---|---|---|
| Price | $39.84 | $103.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 22 |
| Target Price | $69.93 | ★ $103.82 |
| AVG Volume (30 Days) | ★ 4.0M | 1.8M |
| Earning Date | 02-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 227.45 | 6.74 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,537,927,000.00 | $982,021,000.00 |
| Revenue This Year | $14.31 | $29.73 |
| Revenue Next Year | $13.96 | $27.71 |
| P/E Ratio | $196.90 | ★ N/A |
| Revenue Growth | 18.11 | ★ 32.88 |
| 52 Week Low | $35.39 | $34.91 |
| 52 Week High | $83.36 | $120.74 |
| Indicator | NTNX | GH |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 54.13 |
| Support Level | $40.18 | $104.90 |
| Resistance Level | $41.78 | $110.46 |
| Average True Range (ATR) | 1.67 | 6.38 |
| MACD | 0.52 | -0.05 |
| Stochastic Oscillator | 71.40 | 60.66 |
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.